Grifols (GRFS) Change in Taxes (2010 - 2016)
Grifols' (GRFS) quarterly Change in Taxes came in at -$194.8 million in Q3 2016, down 340.17% YoY from $81.1 million in Q4 2015, and down 340.17% on a QoQ basis from $81.1 million in Q3 2015.
Grifols (GRFS) Change in Taxes (2010 - 2016) Analysis & Trends
Grifols (GRFS) has 7 years of Change in Taxes data on file, last reported at -$194.8 million in Q3 2016.
- Quarterly Change in Taxes fell 340.17% year-over-year to -$194.8 million in Q3 2016, while the trailing twelve-month figure through Sep 2016 was -$8.7 million (down 104.06% YoY) and the FY2011 annual result came in at $19.3 million, up 143.86% from the prior year.
- Change in Taxes slipped to -$194.8 million in Q3 2016, from $81.1 million in the prior quarter.
- In the past five years, Change in Taxes ranged from a high of $81.1 million in Q3 2015 to a low of -$194.8 million in Q3 2016.
- A 5-year average of $3.8 million and a median of $45.5 million in 2014 frame the typical range for Change in Taxes.
- Annual changes were most pronounced in 2013 — Change in Taxes soared 116.9% — and 2016, when it sank 340.17%.
- Tracing GRFS's Change in Taxes over 5 years: stood at $27.4 million in 2012, then soared by 116.9% to $59.5 million in 2013, then retreated by 23.52% to $45.5 million in 2014, then soared by 78.2% to $81.1 million in 2015, then slumped by 340.17% to -$194.8 million in 2016.
- The last three Change in Taxes figures came in at -$194.8 million (Q3 2016), $81.1 million (Q3 2015), and $45.5 million (Q3 2014), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.22 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -131.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 171.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | -194.84 Mn |
| Sep 30, 2016 | -194.84 Mn |
| Sep 30, 2015 | 81.12 Mn |
| Sep 30, 2015 | 81.12 Mn |
| Sep 30, 2014 | 45.52 Mn |
| Sep 30, 2014 | 45.52 Mn |
| Sep 30, 2013 | 59.52 Mn |
| Sep 30, 2013 | 59.52 Mn |
| Sep 30, 2012 | 27.44 Mn |
| Sep 30, 2012 | 27.44 Mn |
| Dec 31, 2011 | 10.87 Mn |
| Dec 31, 2011 | 10.87 Mn |
| Sep 30, 2011 | 13.48 Mn |
| Sep 30, 2011 | 13.48 Mn |
| Dec 31, 2010 | -15.59 Mn |
| Dec 31, 2010 | -15.59 Mn |
| Sep 30, 2010 | -3.12 Mn |
| Sep 30, 2010 | -3.12 Mn |